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INTRODUCTION
Prostate is one of the major accessory sex gland of male reproductive
system. The prostate is a pyramidal shaped organ made up of fibro muscular
and glandular tissue and it surrounds the prostatic urethra from the base of the
bladder to the membranous part of urethra. The prostate was initially divided
into five anatomical lobes. Now it is recognized that five lobes only
distinguished in fetal gland before the 20 weeks’ of gestation. In normal adult
male only three lobes are recognizable which includes two lateral lobes which
can be easily palpated via the rectum and a median lobe which when enlarges
can be well identified by ultrasound (USG) and other imaging modalities.
Prostate has exocrine functions. But its role as endocrine organ is not
fully established. Prostate secretes about 0.5 ml of the total seminal fluid
which accounts for about one sixth of the seminal fluid. Multiple secretory
protein products have been identified from the prostatic fluids. Important
among these products are prostate specific antigen also known as PSA and
acid phosphatase. These two products are useful in patients with cancer
prostate.
As the age increases prostate continue to enlarge under the influence
of dihydrotestosterone and testosterone. Enlargement of the organ can lead to
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bladder neck obstruction which produces variety of lower urinary tract
symptoms.
Benign prostatic hyperplasia (BPH) is one of the most common problems
of aging males all over the world. Benign prostatic hyperplasia produces
variety of lower urinary tract symptoms (LUTS) which can lead to simple
disturbances in work to severe restriction of day today activities leading to
poor quality of life.
The exact prevalence and incidence of BPH cannot be quantified
because of BPH is an age dependent illness. The development of BPH starts as
early as 40 years of age. BPH prevalence is greater than 50% by the age of 60
years and by the age of 85years BPH prevalence is as high as 90%.(1) As the
age increases, bothersome symptoms also tends to increase with age.
Prostate enlargement in old age was described by various names which
include benign prostatic hyperplasia (BPH), benign prostatic enlargement
(BPE), or benign prostatic obstruction (BPO), benign prostatic hypertrophy,
etc. Enlargement produce wide variety of symptoms which are known as
lower urinary tract symptoms (LUTS) and they can classified as obstructive
and irritative. Previously they were named as voiding and storage symptoms
respectively. It includes hesitancy, thin stream, intermittency, post void
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dribble, decreased force of urination, straining, nocturia, frequency and
dysuria.
Prostatic enlargement is not the only cause for LUTS, also there are list
of other conditions which may cause LUTS. Hence, the evaluation of patients
with LUTS should go well beyond clinical evidence of enlarged prostate. It
includes detailed history, clinical examination, per rectal examination followed
by ultrasound, subjective assessment of symptoms in the form of various
questionnaires and objective evidence of assessment of symptoms by
uroflowmetry and invasive pressure flow studies.
Management of the patients diagnosed with enlarged prostate due to
benign prostatic hyperplasia depends on symptomatology of the patient and
objective assessment results. Treatment options available range from simple
watchful waiting to open prostatectomy. In between the spectrum are medical
management with alpha blockers or 5 alpha reductase inhibitors and various
minimally invasive and endoscopic procedures like TURP, Transurethral
needle ablation of prostate (TUNA), transurethral ultrasound–guided laser-
induced prostatectomy (TULIP), transurethral vaporization of the prostate
(TUVP), transurethral incision of prostate (TUIP). Surgical treatment provides
sustainable long term results in the management of BPH. In the modern era of
endoscopy the need for open procedure becomes less and less but still it has its
own value in certain situations like large prostate more than 75 grams, BPH
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with large bladder diverticulum, associated large vesical stone with enlarged
prostate and conditions not allowing to place patient in lithotomy position like
ankylosis of hip. Among the endoscopic options TURP is considered as a
“gold standard” treatment for enlarged benign prostate and most commonly
done surgical procedure for BPH. (25) Indications and treatment methods for
enlarged prostate are well established. TURP can be done by using monopolar
cautery or bipolar current. Monopolar is already established and gold standard
procedure against which all other modalities are compared. Improvements in
technology and modifications in instruments and various new advances in
electrocautry have brought about huge reductions in morbidity and mortality,
but the basic principles of TURP remain the same. Bipolar TURP is now
increasingly done procedure for benign enlargement with an added advantage
of reduced complications but it is not fully replaced the monopolar TURP and
till date monopolar is considered as gold standard.
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AIM AND OBJECTIVE
The primary aim and objective of the present study is to compare the
clinical outcomes in terms of symptom improvement and early postoperative
results after monopolar or saline resection TURP for benign prostatic
hyperplasia and with a secondary objective to study the advantages of saline
transurethral resection over monopolar transurethral resection.
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REVIEW OF LITERATURE
Prostate is one of the major accessory sex gland of male reproductive
system. It secretes about 0.5 ml of prostatic fluid which constitutes about one
sixth of the total seminal secretion. Enlargement of the prostate occurs as the
male becomes aged and produce lower urinary tract symptoms (LUTS).
Medical and surgical treatments are available for the management of these
symptoms. Minimally invasive and endoscopic procedures are mainstay in the
treatment of this condition in which TURP is the ‘gold standard’ against which
all other newer modalities are compared.
PROSTATE
EMBRYOLOGY OF PROSTATE;
Prostate develops during 10th week of intrauterine life. It is a
derivative of primitive endoderm. It develops from the caudal part of
urogenital sinus from which the proliferation of epithelial buds occurs. This
part is later invaded by the process known as “mesenchymal condensation”.
This condensation is androgen independent process which occurs in both
males and females but epithelial budding is an androgen-dependent process
and it is the first event in the development of prostate. Epithelial-mesenchymal
interactions are very important for the development of prostate. Androgens
presence alone not important for development but it should also present in
sufficient quantity.
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ANATOMY
Prostate is pyramid shaped gland located at the neck of the bladder and it
surrounds the prostatic urethra. Prostate is fibro muscular gland and lies behind
symphysis pubis. It measures about 3cm in length and 4cm in width and 2cm
in depth. Prostate weighs about 14 to18gm in normal adult male but it weight
increases as the age increases.
It has no true fibrous capsule. Prostate is enclosed by visceral fascia
which contains the neurovascular tissue. This capsule is made up of collagen,
elastin, and abundant smooth muscle and it is firmly adherent to gland and
forms numerous fibro muscular septa which divide the prostate glands into
indistinct lobules. It is attached to pubis by puboprostatic ligament anteriorly
and urogenital diaphragm supports the inferior part. Prostate is traversed by
urethra and posteriorly perforated by ejaculatory ducts, and it contains the
prostatic utricle.
Figure 1. Cut Section of Prostate
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Prostate is composed of 70% of glandular structures and remaining
30% composed of fibro muscular stroma. It is made up of tubuloalveolar gland
type.
Lowsley classified the prostate into 5 lobes which are anterior lobe,
posterior lobe and median lobe which project into bladder when it enlarged
and right lateral and left lateral which are situated on both sides of the urethra.
Franks divided the prostatic tissue with an inner (urethral) and outer glandular
configuration. (2)
Figure 2. Zonal anatomy of prostate – coronal plane.
McNeal and Lowsley proposed that the inner urethral glands should be
considered separately from the prostate and its intrinsic architecture.(3,4)
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According to McNeal, the urethra separates the prostate tissue into
ventral or anterior part (fibromuscular) and dorsal or posterior part (glandular).
McNeal divided the glandular prostate into four regions: peripheral zone,
central zone, transition zone, and periurethral gland region.
Figure 3.Zonal anatomy of prostate – sagittal plane.
BPH occurs in transitional zone and malignancy, inflammation of
prostate develops from the peripheral zone. The central zone surrounds the
ejaculatory duct and peripheral zone is cup-shaped and it encloses the central
transitional zone and also the preprostatic urethra except anteriorly.
Prostate derives it blood supply through the inferior vesical, internal
pudendal, and middle rectal arteries. Inferior vesical artery divides into
urethral and capsular branches. Posteriorly at 5 and 7 o’ clock position urethral
branches enter the prostate at prostatovesical junction and anteriorly at 1 and
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11 o’clock position. This landmark is important during TURP and open
surgeries. Prostate is drained by peri prostatic plexus which further drains into
deep dorsal vein of penis and internal iliac veins. Main lymphatic drainage is
by internal iliac, sacral and obturator nodes.
BENIGN PROSTATIC HYPERPLASIA (BPH)
HISTORY
Urinary obstruction due to prostatic disease was described even in the
olden days of medicine. The relationship between BPH and urinary obstruction
initially proposed by Riolan as early as 17th century and further added by
Morgagni in mid- 18th century. Morgagni proposed the one of the earliest
descriptions of BPH (5). Virchow identified the specific pathologic process in
19th century. Even after the understanding the pathologic process exact cause
BPH remains elusive.
AETIOPATHOGENESIS
Benign Prostatic Hyperplasia is appropriately defined as “histological
enlargement of the prostate gland from progressive hyperplasia of stromal and
glandular prostatic cells”. Such a hyperplasia usually begin in the part of
urethra which is surrounded by prostate because increased number of glandular
elements in the above mentioned area.
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Growth of the tissue result from proliferation of the fibroblast or
myofibroblast and epithelial glandular elements. Gland formation is usually
occur only during gestational life. But this process of gland formation once
again started in enlarging prostate gland is suggesting that reawakening of
inductive potential which usually only seen during fetal development.(7)
Figure 4. Stromoglandular hyperplasia( 6)
Aetiology of this process is uncertain. The process of hyperplasia occurs
in multifocal manner and it exhibits variegated histology mixed with different
ratios of stromal nodular and glandular hyperplastic areas.(8)
Factors important in aetiology are,
1. Androgens,
2. Oestrogens,
3. Stromal-epithelial interactions,
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4. Regulation of Programmed Cell Death
5. Growth Factors,
6. Neurotransmitters
HORMONAL FACTORS
Hormonal factors such as androgens and oestrogens are playing a role in
enlargement of prostate. The development of prostate requires the presence of
testicular androgens namely testosterone and dihydrotestosterone (DHT).
Androgens are required not only for proliferation and differentiation but also
for actively inhibiting the cell death. When BPH is produced experimentally
by androgens, despite an increase in the size of gland, there is actually a
decrease in the rate of DNA synthesis.(9) Enzyme 5α-reductase which is
normally found in nuclear membranes converts the hormone testosterone into
DHT, which is the important, potent and active androgen in prostatic tissue
because of its increased affinity for androgen receptor (AR). Binding of
androgen to AR leads to receptor activation and which in turn bound with
specific DNA sites in the nucleus which results in increased transcription of
androgen dependent genes resulting in protein synthesis.(10) Castrations before
puberty and other gene factors that reduce androgen production resulting in
failure of development of BPH. Androgen withdrawal in established BPH
leads to reduction in the size of BPH. Androgen withdrawal exert its effect by
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vascular effects, inactivation of key androgen dependent genes like PSA and
also by activation of key genes involved in programmed cell death. (11)
Another hormone Oestrogen play an unclear role as compared to its role
in dogs where it play a role in pathogenesis of benign enlargement.
APOPTOSIS
It is also known as programmed cell death. Apoptosis is a physiologic
mechanism important for the maintenance of normal glandular homeostasis. It
occurs without activation of immune mechanism. It needs RNA and protein
synthesis. Following castration, active cell death is more in luminal epithelium
and also in distal part of prostatic ducts. TNF-β family of cytokines needed
for this process. (12)
EMBRYONIC REAWAKENING THEORY
Paracrine type of communication exists between stroma and epithelium.
Defect in the stromal component which normally inhibits cellular proliferation,
leading to loss of normal braking mechanism. This process of new gland
formation in the hyperplastic prostate suggests a “reawakening” of embryonic
processes in which underlying prostatic stroma induces epithelial cell
development. (13)
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GROWTH FACTORS (GF)
These are proteins made of peptides that stimulate, or inhibit, cell
division and differentiation processes. Cells that respond to growth factors
have on their responding cells, cell surface receptors specific for that growth
factor. Receptor in turn linked to a variety of trans membrane and intracellular
signalling mechanisms. Lawson's team was the first to demonstrate that
extracts of BPH stimulate cellular growth. This factor late found out as basic
fibroblastic growth factor (b-FGF). (14)
Stimulatory growth factors includes,
1. Basic fibroblast growth factors
2. Acidic fibroblast growth factors
3. Integrin-2
4. Keratinocyte GF
5. Epidermal GF
6. Vascular endothelial growth factor (VEGF)
7. Insulin-like GF
Inhibitory factors,
1. Transforming growth factor-β
- Down regulated in hyperplasia
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Figure 5 : Molecular control mechanisms involved in the development of hyperplasia
Inflammatory cell may act as source of these growth factors. Theyer and
associates found increased number of inflammatory T cells in prostatic tissue
of patients with BPH. (26)
OTHER SIGNALLING PATHWAYS
Sympathetic signalling pathways also play a role in the pathophysiology
of LUTS. Evidence is increasing that alpha blockade, in some model systems,
can induce apoptosis. Renin-angiotensin system (RAS) also are present in
prostatic tissue and may be activated in BPH. (11,12)
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PATHOLOGY OF BPH
 
Figure 6 : Pathophysiology of benign prostatic hyperplasia
Hyperplasia occurs in the periurethral transition zone of prostate.
Imbalance between death and proliferation of epithelial and stromal cells lead
to enlargement of the prostate. It is marked by proliferation of glandular
tissue which is the earliest change with minimal alteration of stromal elements.
Marked variability in stromal-epithelial ratios, such as small glands have
predominant fibro muscular stroma and large glands demonstrate mainly
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epithelial nodules. Smooth muscles play an important role in pathophysiology
of BPH.
On the basis of autopsy studies, Barry and colleagues suggested that
BPH is a gradually progressive disease which commences in men in their 40
years of age. Baltimore Longitudinal Study of Aging suggests the progressive
nature of the enlarged prostate in aging males. The prostate volume increase
by about 0.6 ml per annum. Mean fall in flow rate is about 0.2 ml/s/year
SYMPTOMS
Enlargement of produce wide variety of symptoms which are known as
lower urinary tract symptoms and they can classified as obstructive and
irritative. Previously they were named as voiding and storage symptoms
respectively. The term lower urinary tract symptom (LUTS) was coined by
Paul Adams. (Chapple et al, 2008).(27)
OBSTRUCTIVE SYMPTOMS
1. Hesitancy,
2. Thin stream,
3. Intermittency,
4. Post void dribble,
5. Decreased force of urination
6. Straining
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IRRITATIVE SYMPTOMS
1. Nocturia
2. Frequency
3. Dysuria
EVALUATION OF BPH
Symptoms are the primary guidance in the management of BPH, hence
adequate evaluation and the subjective assessment of the symptoms should be
done. Initial evaluation is begins with detailed history with complete and
systematic examination including detailed per rectal examination (DRE) and
focussed nervous system examination. This is followed by complete urine
analysis, culture and sensitivity and assessment of renal functions.
ULTRASOUND
Either Trans abdominal or Trans rectal can be done with Trans
abdominal being more common .Trans abdominal USG uses 3.5 MHz probe
and high frequency 7-10 MHz probes in Trans rectal ultrasound. Volume of
prostate calculated by depending on the shape of the prostate like if prostate is
ellipse (pi/6 × transverse diameter × AP diameter × longitudinal diameter),
sphere (pi/6 × transverse diameter3), or a prelate (egg-shaped) spheroid (pi/6 ×
transverse diameter2 × AP diameter).
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Upper urinary tract imaging is only recommended in,
1. Patients presenting with haematuria,
2. Associated or suspected urinary tract infection,
3. Elevated renal parameters
4. History of renal stones
5. Previous genito - urinary tract surgery.
Ultrasound abdomen and pelvis advised in previously mentioned
conditions with due importance also given to measure prostate volume and
residual urine. Post void residual (PVR) is defined as “ the amount of urine
which remains in the bladder immediately after micturition”. Catheterisation
techniques and USG has been used to measure PVR. The mean PVR in
normal patients is about 0.53ml. (17)
In above conditions patient may need a computerized tomography for
complete evaluation. Serum PSA (Prostate Specific Antigen) is done in
patients with the family history of prostate cancer and suspected DRE findings.
This subjective assessment is not without problems because of each
individual has different tolerance levels for symptoms hence various symptom
scales were devised and validated on large groups of populations. The most
useful, most validated and commonly used scale is the IPSS (The International
Prostate Symptom Score). This scoring system is recommended as tool for
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evaluating patients present with LUTS.(18) In addition to the subjective
assessment ,objective assessment is done with uroflowmetry which asses the
urinary flow rate. This test is easily available and can be done at bedside. The
peak flow, mean flow and voiding times of the patient are measured by
uroflowmetry test. Even though urodynamic studies are considered as gold
standard test (19) for evaluating the patients with LUTS they are not routinely
done for all BPH patients.
 
Figure 7 : Guideline algorithm for Evaluation of benign prostatic hyperplasia.
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Urodynamic studies may be indicated in following situations, (EAU 2012)
a. cannot void > 150 mL;
b. When Qmax is less than 15 ml/second,
c. Age less than 50years or more than 80years,
d. Patients with more than 300 ml of residual urine ,
e. Suspicion of neurological bladder dysfunction,
f. Patients with both side hydronephrosis,
g. Previous radical surgery in pelvis,
h. Failed invasive treatment.
EVALUATION - INTERNATIONAL PROSTATE SYMPTOM SCORE
It is also known as ‘American urological association symptom index’
(AUASI). The Measurement Committee of the American urological
association (AUA) developed the IPSS/AUASI.(20) AUA/IPSS symptom score
is reliable, validated and clinically useful scale to subjectively measure the
symptoms and problem magnitude of the patients with benign enlargement of
prostate. IPSS cannot be solely used to confirm the diagnosis of prostate
enlargement. IPSS is the available best tool to grade the symptom severity,
assessment of responsiveness to therapy and used to detect the symptom
progression in patients with BPH who are managed with conservative
management. Multiple factors should be considered before using IPSS
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questionnaires.(21) First, internal consistency reliability of the test must be
confirmed .Next, the test-retest reliability of the given questionnaire should be
established. This may be done by demonstrating the minimal change of the
given results when the test is repeated on the same patients after a short period.
Third, a questionnaire should have the same degree of accuracy as any other
diagnostic test used to assess the disease process. To considered as valid test,
the symptom score results must exactly quantify the severity of BPH (“as
serum lipid levels test reflecting the disease status in patients with
hypercholesterolemia”). Finally, these scales should be useful in
discriminating among the patients who get better or get worse, or remain the
same with or without proposed treatment over a period of time. Based on
above criteria the AUA/IPSS questionnaire is highly reliable and valid scale
for evaluating men with LUTS. Internal consistency reliability and 1-wk test–
retest correlation for IPSS was about 0.86 and 0.92, respectively. (20)
The IPSS score consists of seven questions corresponds to symptoms
commonly seen in patients with BPH. They are,
1. Incomplete emptying,
2. Frequency,
3. Intermittency,
4. Urgency,
5. Weak stream and
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6. Straining
7. Nocturia
Every question have zero to five points when all added together gives a
score between zeros to thirty five. Point 0 stands for not at all patient
experienced the symptom and 5 for almost always patient having the
symptoms.
Based on total IPSS patients can be classified into having mild,
moderate or severe symptoms. (22)
0-7 - Mild symptoms
8-19 - Moderate symptoms
20-35 - Severe symptoms
Only assessment of IPSS alone does not helpful in confirming the BPH,
because patient’s perception of symptoms are different for each patients.
Overall, the IPSS is reliable and valid through a variety of testing
modalities.(21). Apart from this score, different types of scores like bother score
and QoL index are useful in deciding the further management.
QUALITY OF LIFE (QOL) INDEX
The QoL index (Appendix 5) is a single question item which is assessed
along with AUA symptom index and is considered as a part of the IPSS score.
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QoL assess the degree to which the symptoms bothering the patient. Response
ranges from 0-6.
UROFLOWMETRY
Uroflowmetry is “rate of urine flow over time.” It is done by graphic
recording of the urinary flow rate during the act of voiding. It is commonly
used simple, non-invasive, and easily available. It is nonspecific test. Peak
flow rate cannot differentiate BOO from impaired detrusor contractility. It is
used as screening test for voiding problems & for deciding need for more
complex urodynamic tests.
Modern uroflowmeters use,
1. Use weight, (Gravimetric method)
2. Electrical capacitance, or
3. Rotating disc.
The regularly used meters are the Gravimetric flow meters which
functions by measuring the weight of the collected urine or by measuring the
hydrostatic pressure developing at the base of the collecting cylinder during
the act of micturition. Flow measured in ml/second.
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Figure 7.Normal bell shaped uroflow curve
The AHCPR Guideline for uroflowmetry (McConnell et al, 1994) (18)
1. Flow rate is not correct if patient passes less than 125 to 150 ml of urine.
2. Flow rate is the single best non-invasive test for detecting the
obstruction below bladder. No “cut-off” value fixed so far.
3. The peak flow rate (PFR; Qmax) is more specific in BPH
4. No adjustment in values for change in age and decreasing voided
volume
5. Qmax more than 15 mL/sec may be associated with poorer surgical
outcomes after prostatectomy.
6. A Qmax less than 15 mL/sec can’t separate bladder obstruction from
decompensation.
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Qmax is shown to predict the response to surgery. It is a useful test in
follow up of patients treated for BPH.
URETHROCYSTOSCOPY
Urethrocystoscopy is not routinely recommended. It is only
recommended in following situations,
1. History of microscopic or gross haematuria,
2. Urethral stricture disease
3. Suspected neoplasm of bladder
4. Prior surgery
5. When surgical treatment is planned.
MANAGEMENT
Management of men with enlarged prostate depends on symptom
severity which is assessed by IPSS and other associated factors and patient’s
willingness for given treatment. As for any other disease both medical and
surgical managements are available apart from watchful waiting.
Watchful waiting is advocated for patients with mild or moderate score
which is not affected the day today activities of the patient.
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Treatment options available for patients with bothersome moderate to
severe symptoms of BPH (IPSS > 8) include watchful waiting and the
medical, minimally invasive, or surgical treatment.
Management of the patients diagnosed with enlarged prostate due to
benign prostatic hyperplasia depends on symptomatology of the patient and
objective assessment results. Treatment options available range from simple
watchful waiting to open prostatectomy. In between the spectrum are medical
management with alpha blockers or 5 alpha reductase inhibitors and various
minimally invasive and endoscopic procedures like TURP, Transurethral
needle ablation of prostate (TUNA), transurethral ultrasound–guided laser-
induced prostatectomy (TULIP), transurethral vaporization of the prostate
(TUVP), transurethral incision of prostate (TUIP) are various endoscopic
options available for the treatment of BPH . Surgical treatment provides
sustainable long term results in the management of BPH as compare with the
medical management with drugs.
MEDICAL MANAGEMENT
For the treatment of enlarged prostate with medications, two groups of
drugs are available. First one is alpha receptor blockers and second group is 5-
alpha reductase inhibitors.
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Alpha blockers act by decreasing the tone of the bladder neck and
prostatic smooth muscle. They are divided into
1. Non selective - Phenoxybenzamine
2. Alpha 1 selective – Prazosin, Alfuzosin IR, Indormin.
3. Long acting alpha I selective - Doxazosin, Terazosin, Alfuzosin SR
4. Super selective - Tamsulosin and Silodosin.
Most commonly used one is Tamsulosin which is super selective alpha
blocker. Newer addition is Naftopidil.
The 5 alpha reductase inhibitors, inhibit 5 alpha reductase which
converts testosterone into dihydrotestosterone. The drugs are finasteride and
dutasteride. They reduces the prostate size on long term treatment. 20%
reduction in volume has been reported with finasteride use alone.(23) Safety and
efficacy of these drugs are well established but clinical improvement is modest
and not sustainable. Most of the patients with mild to moderate symptoms on
medications slowly progress into higher groups and may need surgical
treatment as a definitive management. Drugs are mainly used in patients with
mild symptoms and small glands.
SURGICAL MANAGEMENT
Most commonly done surgical procedure for BPH treatment is
endoscopic transurethral resection of the prostate and this procedure is
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considered as gold standard for the treatment of BPH. TURP is commonly
done by using monopolar energy and nowadays rise in the usage of bipolar
TURP.
HISTORY OF ELECTROSURGERY AND THE RESECTOSCOPE
The invention of incandescent lamp by Edison, the cystoscope by Nitze
and Lieter, the development of fenestrated tube by Hugh Hampton-Young and
the resection wire loop by McCarthy were important in the field of
endourology which reduced the rate of open surgeries in urology with less
morbidity to the patient with desirable results.
In 1932 McCarthy designed tungsten loop for resection and it was
developed with available cystoscope, light and electrical power and high
resistance loop. In 1970 advent of Hopkins rod lens system and fiberoptic
lighting made visualization better. In 1980 video urological procedures were
introduced. Thick loop electrode allowed for increased coagulation while
removing larger tissue bits.
The first commercial bipolar coagulator was designed and built by
Dr.malis in 1955. This bipolar system uses a 1 MHz waveform for cutting and
coagulation of tissues. A majority of monopolar systems use1000-3000 Vrms.
Bipolar system uses only about 220 to 320 Vrms, because of this reduced
amount localized tissue damage.
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The advantages of bipolar system are,
1. Less tissue dehydration, carbonization and tissue reaction.
2. Less bleeding
3. Can be used in patients with cardiac implant devices.
4. Clear view at operative site
5. No grounding pads
6. Can be used in saline
7. Minimal tissue damage
8. Less tissue charring
9. Distinct circuitry and waveforms.
In 1926, Stern was the one who introduced resectoscope subsequent to
which there have been modifications in the resectoscope design. (28)
The resectoscope designed by Stern was a rack and pinion model which
was operated by both the hands and a tungsten loop slid front and back to
make the resection. It had an outer sheath which allowed irrigation, passage of
telescope and working element. With the Stern resectoscope sheath a tubular
cylinder of tissue was resected using high frequency current. Although
effective in resecting the prostatic mass, it was difficult to engage the bladder
tumours with this instrument. (28)
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McCarthy who modified the Stern resectoscope by incorporating
Bakelite to the tip of the sheath and thereby making it possible to work when
the current was applied and also prevented the risk of electric burns to the
operating surgeon.(29) Nesbit is regarded for his unique contribution of single
handed spring action working element which permitted safe resection. (30)
Iglesias proposed a model as early as 1979 is which is very much similar
to Nesbit, he introduced the continuous flow resectoscope sheath which
speeded up the resection at the compromise of larger sheath size. The Iglesias
sheath essentially had two sheaths, of which the larger outer sheath for
irrigation and smaller inner one for drainage. Advantages of this design
include it is operated by single hand, loop is inside the sheath in resting
position and unique continuous flow design which keep the bladder pressure
low and a buy in the resection time. Thus the incidence of TUR syndrome
should be theoretically low.(31)
Monopolar TURP
TURP can be performed under spinal or general anaesthesia. First
cystourethroscopy done after dilating the urethra. Before proceeding with the
resection a thorough inspection of urethra, verumontanum, prostate, bladder
neck, entire bladder mucosa and both ureteric orifices is done. 24 Fr or 27 Fr
resectoscope used for resection of the prostate. Either sterile water or glycine
is used as the irrigant. Thick loops are usually used. The technique used for
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resection was first described and standardised by Nesbit in 1943 (24) and later
modified and by many investigators. But the basic principles remain the same.
Controlled resection, limiting the resection proximal to verumontanum, not
violating the capsule and not undermining the bladder neck remains the most
important steps of TURP. Complications include
1. Bleeding,
2. Trans urethral resection syndrome,
3. Priapism,
4. Post -operative incontinence,
5. Failure to void, etc.
Bipolar-TURP
The surgical technique is similar to monopolar. In monopolar electro
surgery the electric current is passes from the active loop then through the
tissues (patient), and exits through the indifferent electrode placed abutting the
patients skin and back to the electro surgical unit to complete the circuit. The
heat generated at the loop-tissue interface is used for resection.
In bipolar the large return electrode of the monopolar is replaced with a
second small electrode. The path of the electric current is from the active loop,
through the conducting irrigant, through the patient’s tissue, to the second
indifferent electrode which is placed very close within the same loop and then
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back to the electrosurgical generator. Two electrodes are combined in the
instrument. Current passes between tips and not through patient. Hence, there
is no current flowing through the patient’s body.
CREATION OF PLASMA
In Bipolar resection, Current flows through the saline because
impedance is lower in saline than in body tissue. Air bubbles are created
around the loop by the heat caused from current flow. The whole loop is
covered by small bubbles.
 
Figure-10 Endoscopic view showing orange colour plasma
Finally the loop is coated by an insulation layer. At this point Sodium
ions are excited. Current is discharged to the air surrounding the electrode,
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similar to lightning. Then the electrode is covered by plasma. Resection is
made by the heat of the plasma created around the electrode (Figure-8).
Figure -8 Formation of PLASMA
The colour of plasma formed in saline is orange colour and it depends
on ion present in the irrigation fluid. The path of the current in resection loop
is from active electrode, through the saline, through the tissue and back to the
indifferent electrode close to active loop.
               
Figure-9 picture showing bipolar loop with plasma
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A number of bipolar loop designs are available in the market depending
on the manufacturer.
VARIOUS LOOP DESIGNS
GyrusStorz
Olympus
Active
Current path
Neutral
Current path
Current path
Neutral
NeutralActive
Active
The loops are designed so that both the electrodes are placed closely.
The Olympus system used the resectoscope sheath as the neutral electrode.
The Gyrus loops are so designed that the neutral electrode is incorporated into
the stem of the loop and active and neutral electrodes are separated by
insulation.
Various randomized and nonrandomized studies were conducted all
over the world and they compared the safety and outcomes of the monopolar
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and bipolar TURP. Monopolar TURP is till now the gold standard procedure
in the endoscopic management of BPH but certain morbidities like
intraoperative bleeding, fall in haemoglobin, fall in sodium and TUR
Syndrome can occur with monopolar TURP.(34) These complications can be
reduced by using bipolar TURP and various studies had shown different
results with bipolar TURP. Even though these advantages were studied and
efficacy and safety of bipolar TURP have been published, still monopolar
TURP remains the gold standard for BPH.
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MATERIALS & METHODS
The following are the materials and methods employed for the present
study titled “COMPARISON OF OUTCOMES OF MONOPOLAR
TRANSURETHRAL RESECTION VS SALINE TRANSURETHRAL RESECTION
(BIPOLAR) OF PROSTATE IN PATIENTS WITH BENIGN PROSTATIC
HYPERTROPHY”.
Period of study:
The study is done between April 2012 and Feb 2013
Type:
This is a prospective study to compare the clinical outcomes in terms of
symptom improvement and early postoperative results after monopolar or
saline transurethral resection of prostate for benign prostatic hyperplasia.
Place:
The study is conducted in the Department of Urology, Rajiv Gandhi
Government General Hospital & Madras Medical College, Chennai.
Inclusion criteria
Patients of age more than 50 years with lower urinary tract symptoms
due to benign prostatic hypertrophy
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Exclusion criteria
• Prostatic cancer,
• Urethral stricture,
• Neurogenic bladder,
• Prostatitis,
• Active urinary infection and
• Previous Prostate surgery.
• Patients with coagulopathy
Method of Study
Institutional Ethics Committee approval was obtained. Informed consent
was taken from all patients who underwent surgery. All patient details were
recorded as per the proforma (Appendix-4). Patients were randomized into two
groups of 75 each to undergo TURP either with Monopolar TURP (Group 1)
or saline bipolar transurethral resection (Group 2). In monopolar group
(Group 1) Glycine was used as irrigant and in bipolar group ( Group 2) saline
was used as irrrigant.(32) We used the Gyrus ACMI PK system and used PK
thick loop for resection for bipolar group. The settings we employed was
160W cutting and 80W coagulation for bipolar resection. Martin ME MB2
monopolar system was used for monopolar TURP and the setting used was
120W for cutting and 60W for coagulation.
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The setup of instruments for monopolar TUR resection is well known. It
includes 24 – Fr. Karl Storz non-continuous flow sheath with blind and visual
obturator, resectoscope, monopolar loop, high frequency cord, 30 degree Karl
Storz telescope and diathermy. But the setup used for bipolar TUR resection is
almost the same as monopolar with certain modifications as mentioned below.
The working element is modified and has no shaft. There is a modified
slot for engaging the bipolar loop. The working element is provided with an
adaptor so that it can easily and correctly fit into the regular resectoscope
sheath normally used for monopolar. The resection loop used in bipolar group
also different from the conventional monopolar loop. It is much sturdier to
compensate for the shaft which is absent in working element. The high
frequency cable is integrated into the loop hence loop cannot be separated
from the cable as we does in monopolar loops. There is also a leak proof wiser
present in the shaft of the loop.
The basic setup for bipolar resection is given in the figure below.
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GYRUS ACMI PK SYSTEM
Full Bipolar Set Working Element With Bipolar Loop
           
Modified working element Assembled bipolar set
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PREOPERATIVE WORKUP
Complete clinical history was taken from all patients. Preoperative IPSS
and quality of life index score (QoL) was recorded for all patients. Co-morbid
conditions like Hypertension, Diabetes Mellitus, and Ischemic Heart Disease
were documented. Complete and systematic examination of the patients were
done including genital and rectal examination.
In both the groups complete urine analysis, Urine culture and sensitivity
were done and patients with positive cultures were treated with appropriate
antibiotics. Complete haemogram and renal function tests with electrolytes,
(sodium, potassium) coagulation parameters, Blood grouping and typing were
done in the preoperative period. X-ray KUBU was taken and Ultra sonogram
of KUB region was done. Uroflowmetry was done for appropriate patients.
Anaesthetic fitness obtained and all the resections were performed by our
Senior Professors they are well experienced in performing TURP.
All patients after exclusion criteria and complete evaluation were
subjected to either Monopolar or Bipolar TURP. Spinal anaesthesia was used
for all patients and patients underwent the procedure in lithotomy position.
Preliminary cystourethroscopy was done to assess the anterior urethra,
verumontanum, prostate gland, and bladder mucosa & ureteric orifices. A 24-F
Karl Storz non-continuous flow resectoscope with Baum Rucker type of active
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working element was used for resection with glycine as irrigant for Monopolar
TURP (Group 1) and saline as an irrigant for Bipolar TURP (Group 2).
The resection time of all procedures were calculated from the period of
initiation of resection to the removal of resectoscope sheath. For all patients,
resection time, any intraoperative complication were noted and 3-way Foley
catheter was inserted at the end of the procedure and irrigation was started and
continued postoperatively. After the procedure specimens were packed
properly and sent to pathology department for histopathological examination.
Postoperatively all patients were monitored for haematuria, altered
sensorium and any change in vital parameters. In the post-operative period
blood sent for haemoglobin, pack cell volume (PCV) and serum sodium, &
potassium. Irrigation continued till next morning as a protocol for all patients
and continued if necessary after that. Catheter removed on fourth postoperative
day and discharged on the same day. Patients were reviewed with biopsy
report and postoperative IPSS, QoL were recorded and Uroflowmetry was
done during first month follow up. Changes in preoperative and postoperative
parameters like IPSS, quality of life (QoL), maximum flow rate (Qmax),
haemoglobin, pack cell volume, sodium were analysed.
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STATISTICAL ANALYSIS
Descriptive statistics were used to illustrate the study population. The
statistical significance of these correlations was assessed using a two sided p-
value. A p-value of <0.05 was considered as statistically significant. The Chi
Square test was used to assess the statistical significance. A commercially
available computer software package ( Statistical Package for the Social
Sciences (SPSS) version 17) was used for statistical analysis.
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RESULTS
Total of 150 patients were randomized and participated in the study.
Demographic data of the group 1 and group 2 are given in Table 1.
TABLE 1. DEMOGRAPHY
FACTORS MONOPOLAR BIPOLAR
TOTAL NUMBER 75 75
AGE IN YEARS 65.33 65.97
ON CATHETER 12 11
DIABETES MELITUS 13 12
HYPERTENSION 12 12
Mean age of patients in monopolar and mean age of bipolar group
patients are 65.33years and 65.97 years respectively. In the both monopolar
and bipolar group, patients with diabetes mellitus, hypertension and on Foley’s
catheter is almost equal. In monopolar group this was 13, 12 and 12 patients
respectively and in bipolar group this was about 12, 12 and 11 patients
respectively. As for as these factors are considered both the groups are equally
matched.
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When comparing the monopolar and bipolar groups regarding the age
distribution and prostate volume it was found that in monopolar group mean
age of the patient was 64.33years and standard deviation was 7.095 and in
bipolar group mean age of the patient was 65.97 years and standard deviation
was 8.269.and statistically there is no difference in both the groups.
(TABLE.2)
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TABLE.2. Age and prostate volume comparison
GROUP N MEAN SD
Age in years
Monopolar
Bipolar
75
75
64.33
65.97
7.095
8.269
Prostate
volume
Monopolar
Bipolar
75
75
35.51
35.59
6.143
5.776
Table 3 : Comparing the preoperative markers such as IPSS, Maximum
flow rate (Qmax), quality of life index (QoL), haemoglobin, pack cell volume
and sodium in monopolar and bipolar group.
TABLE 3.Preoperative data s of monopolar & bipolar group.
VARIABLE Group N Mean Std. Deviation P value
Maximum
flow rate
(Qmax)
Monopolar 64 9.5766 1.01899 .637
Bipolar 63 9.4841 1.18120 .638
IPPS
Monopolar 75 23.17 1.996 .282
Bipolar 75 22.84 1.779 .282
Haemoglobi
n.
Monopolar 75 12.380 .8847 .694
Bipolar 75 12.316 1.0925 .694
PCV
Monopolar 75 36.15 2.593 .833
Bipolar 75 36.05 2.804 .833
Sodium
Monopolar 75 139.60 2.922 .870
Bipolar 75 139.52 3.073 .870
QOL
Monopolar 75 3.93 .723 .826
Bipolar 75 3.96 .761 .826
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Mean of Q max in monopolar group was 9.58ml/second and in bipolar
group was 9.48ml/second. Similarly IPSS in monopolar and bipolar group is
23.17 and 22.84. Quality of life index (QoL) of monopolar and bipolar is 3.93
and 3.96. Mean haemoglobin and PCV in monopolar group was 12.38gm %
and 36.15 as compared to bipolar group value of 12.316gm% and 36.05
which is similar between two groups. Mean sodium level in monopolar and
bipolar is 139.60meq and 139.52 meq respectively. All these preoperative
factors were comparable and equally distributed between both the groups. In
statistical analysis there is no significance found between the groups. So both
the groups are similar as for as pre -operative factors are concerned.
Table.4 compares the prostatic volume and intraoperative resection time
in both monopolar and bipolar groups. Mean prostate volume in monopolar
group is 35.51grams with the standard deviation of 6.185.In bipolar group
mean prostate volume is 35.51grams with the standard deviation of
5.854.Hence prostate volume is similar in both the groups with the p value of
935.
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TABLE 4
Group N Mean Std. Deviation P value
VOL
Monopolar 75 35.51 6.185 .935
Bipolar 75 35.59 5.854 .935
OP TIME
Monopolar 75 41.99 5.020 .001
Bipolar 75 45.11 4.029 .001
Intraoperative resection time in monopolar group is about 41.29
minutes with standard deviation of 5.020 .For bipolar intraoperative resection
time is about 45.11 minutes with standard deviation of 4.029.In Independent
Samples Test this difference is significant with the p value of less than 0.001.
In the post-operative period there was fall in serum sodium,
haemoglobin and change in PCV. Monopolar group had fall off 7 meq of
sodium and in bipolar group it was about 4 meq. This fall in sodium is
statistically significant.
Fall in haemoglobin is about 0.58 gram% in bipolar group and is more
in monopolar group with a fall of 0.71 gram% .But this fall is only in numbers
it is not statistically significant.
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Table 5- Postoperative data
Group N Mean Std.Deviation P value
QMAX -
POST
Monopolar 64 17.7578 .74510 .376
Bipolar 63 17.6349 .81244 .376
IPPS -
POST
Monopolar
75 12.75 1.569 .400
Bipolar
75 12.96 1.528 .400
Hb - POST
Monopolar 75 11.673 .8834 .672
Bipolar
75 11.743 1.1035 .672
PCV -
POST
Monopolar
75 34.47 2.522 .794
Bipolar
75 34.35 3.069 .794
NA - POST
Monopolar
75 132.93 3.090 .001
Bipolar
75 135.29 3.200 .001
QOL -
POST
Monopolar 75 1.87 .577 .650
Bipolar
74 1.82 .558 .650
Also there is change in PCV of about 1.71 in monopolar group and 1.68 in
bipolar group.
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IPSS one of the important parameter which decrease in both the groups
and this fall in score is desirable and it indicates successfulness of surgical
management. Fall in IPSS is about 10.43 points in monopolar group and 9.88
in bipolar group by the end of first postoperative month. This improvement in
symptom score is statistically significant.
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Figure 3.IPSS fall in mono and bipolar group
Maximum flow rate improved by 8.15 ml in bipolar group and 8.18 ml
in monopolar group. Quality of life score decreases by 2.16 in monopolar
group with 2.15 in bipolar group and this change is not significant in between
monopolar and bipolar groups.
Post-operative complications like clot retention, TUR Syndrome and
failure to void were reported after transurethral resection in monopolar group.
In bipolar group there is no incidence of TUR syndrome which occurred in
two the monopolar group .In postoperative complications there is no statistical
difference between two groups.
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Figure 4. Postoperative complications - comparison
In monopolar group three patient developed clot retention and in
bipolar group two patients developed clot retention which was treated with clot
evacuation.
All postoperative catheters were removed on fourth postoperative day
as per protocol and three patients in monopolar and two patients in bipolar
group developed failure to void they were catheterised and started on
medications.
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When comparison of the results are done with in the groups all
preoperative factors had significant changes both in monopolar and bipolar
groups (p<0.001). IPSS, QOL, Qmax all parameters shown improvements.
Table 6 : T- TEST MONOPOLAR
In analysing the results of both the groups, both the group had similar
demographic data and in bipolar TURP resection time is slightly longer as
compared to monopolar because of increased time taken for plasma bubble
formation to be one of the factor or it may be due to learning curve related
factor. In postoperative period both the group shown similar improvements in
Mean N Std. Deviation P value
Pair 1
QMAX - PRE 9.5766 64 1.01899 0.001
QMAX -
POST 17.7578 64 .74510 0.001
Pair 2
IPPS - PRE 23.17 75 1.996 0.001
IPPS - POST 12.75 75 1.569 0.001
Pair 3
Hb - PRE 12.380 75 .8847 0.001
Hb - POST 11.673 75 .8834 0.001
Pair 4
PCV - PRE 36.15 75 2.593 0.001
PCV - POST 34.47 75 2.522 0.001
Pair 5
NA - PRE 139.60 75 2.922 0.001
NA - POST 132.93 75 3.090 0.001
Pair 6
QOL - PRE 3.93 75 .723 0.001
QOL - POST 1.87 75 .577 0.001
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IPSS ,QoL and Qmax. Fall in sodium ,haemoglobin and PCV occurs more
with monopolar group and difference in sodium fall is important and two of
the monopolar patients developed TUR Syndrome which was treated with iv
fluids, hypertonic saline( 3 %).
Table -7. T test bipolar
From the above study safety and equal efficacy of bipolar TURP was
comparable with gold standard monopolar with added advantage of
decreased incidence of TUR Syndrome .
Mean N Std. Deviation P VALUE
Pair 1
QMAX - PRE 9.4841 63 1.18120 .001
QMAX - POST 17.6349 63 .81244 .001
Pair 2
IPPS - PRE 22.84 75 1.779 .001
IPPS - POST 12.96 75 1.528 .001
Pair 3
Hb - PRE 12.316 75 1.0925 .001
Hb - POST 11.743 75 1.1035 .001
Pair 4
PCV - PRE 36.05 75 2.804 .001
PCV - POST 34.35 75 3.069 .001
Pair 5
NA - PRE 139.52 75 3.073 .001
NA - POST 135.29 75 3.200 .001
Pair 6
QOL - PRE 3.96 75 .761 .001
QOL - POST 1.83 75 .554 .001
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DISCUSSION
Benign prostatic hyperplasia is one of the common old age problem in
male population all over the world. Enlargement of prostate leads to
development of variety of lower urinary tract symptoms(LUTS) like
frequency, nocturia , thin stream, intermittency, urgency, incomplete
emptying, straining etc. Enlargement of prostate usually starts around 40 to 50
years of age. By 80 to 85 years age about 90% of the people will develop
symptoms related to benign prostatic hyperplasia. Lower urinary tract
symptoms due to BPH are further divided into obstructive symptoms and
irritative symptoms.
Complete history regarding symptomatology should be elicited and
systematic examination of the patient done with specific importance given to
genital and per rectal examination. After completing the basic workup specific
importance given to uroflowmetry and Qmax recorded. Ultrasound KUB done
and prostate volume measured. International prostatic symptom score (IPSS)
(20) should be recorded along with quality of life index score (QoL)(21).
Depending on the IPSS patients are divided into having mild, moderate or
severe symptoms and treated accordingly.
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Treatment options for benign hyperplasia of prostate include watchful
waiting, medical management and surgical management. Alpha blockers and
5 alpha reductase inhibitors can be given as medical management.(23) Surgical
options varying from minimally invasive procedure to open prostatectomy
depending on the patients need. Treatment is tailored according to patients
symptoms and bothersome produced by enlargement of prostate and comorbid
factors. In minimally invasive procedures transurethral resection of prostate
(TURP) is considered as gold standard (33) and against this yardstick all other
procedure are compared. Traditionally TURP is done with monopolar current
in which current goes through the patient’s body and reach the skin plate
placed at contact point. Monopolar uses high energy. To overcome problems
associated with monopolar TURP ,search was made for alternate treatment
modality which leads to invention of bipolar TURP.
The basic difference in bipolar TURP is current pass through one stem
and returned through another one without going through patients body and it
utilises the lower voltages (220 – 320 Vrms).(34) Creation of plasma bubble at
the resection site is basic principle behind the resection principle of bipolar
TURP. Different type of bipolar loops are available in the market with the
difference in returning pathway either with opposite stem or with the sheath.
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Different type of bipolar working machines are available in the market
which include 1) Gyrus plasma kinetic system or PK system. 2) TURIS
system. 3) Bipolar vista CTR system, 4) Karl Storz system.
Botto et al first used saline in Gyrus device. It has ceramic insulation at
tip. Later PK system was developed.
In our prospective study we used PK system for bipolar TURP. We
randomized 150 patients and 75 patients were underwent bipolar TURP in
saline. In present study demographic data were equal between monopolar and
bipolar group. Resection time was more for the bipolar group as we used thick
loop for resection and resection time found to be a statistically significant
factor. Resection time was 42 minutes-+ 5.020 SD for monopolar group and
45.11+ 4.029 SD minutes in bipolar group. Regarding improvement in IPSS in
monopolar group it is about 10.43 points+1.569 SD and in bipolar it is 9.88 +
1.528 SD at the end of one month. Qmax in monopolar group is 8.18 ml+.75
SD and in bipolar 8.15ml+.81 SD. Quality of life index also shown equal
results between two groups.
Fall in sodium is more with monopolar about 7 meq and it is 4 meq with
bipolar. This is statistically significant (p=0.001). Transurethral syndrome
developed in two of the monopolar group that was promptly recognized and
treated. All other factors were equal between two groups.
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Study by Henry s.s.ho et al 33 totally 100 patients were studied and fall
in sodium level was more in monopolar group, about 10.7mmol higher than
bipolar value of 3.2mmol. This was similar to our study but magnitude of
sodium fall is more in comparison with our study. Resection time has not a
significant factor in their study. Haemoglobin drop was about 1.2+ .6 grams%
but in present study it was 0.71 grams and again magnitude of fall is more in
ho”s study.
Study by Singh H et al (35) shown bipolar is equally effective as
monopolar and monopolar group found to had more sodium drop ( 4.6 meq)
which is similar to results of present study. Again resection time has not a
significant factor in their study.
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Study by chang jun yoon et al (36) shown, bipolar reduces the hospital
stay and early catheter removal.
According to the study conducted at T.N.nair hospital, Bombay India by
Piyush et al (37) difference in sodium fall is about 3 meq which is similar to
present study. Haemoglobin fall in our study is .0.71gm% for monopolar and
0.58gm% for bipolar. In Piyush study it is about .97gm% and 0.55 gm %.
Resection time is more in their study. Only 30 cases were studied in each
group by piyush study compared to 75 cases each in present study.
Limitation and drawback of our study is small number of cases and
short follow up period.
 60
CONCLUSION
1. The present study shows bipolar is as equally effective as monopolar in
reducing the IPSS.
2. Increase in the quality of life and maximal flow rate of bipolar TURP is
equal to the results of monopolar TURP.
3. Our study shows that bipolar has less chance of hyponatremia hence
TUR Syndrome as compared to monopolar.
4. Resection time for bipolar in our study is more, to compare with that of
monopolar.
Bipolar TURP is as safe and equally effective as monopolar TURP but
needs further large randomized trials to confirm the efficacy and safety 
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International prostate symptom score (IPSS) 
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Incomplete emptying 
Over the past month, how often have you had a sensation 
of not emptying your bladder completely after you finish 
urinating? 
0 1 2 3 4 5 
 
Frequency 
Over the past month, how often have you had to urinate 
again less than two hours after you finished urinating? 
0 1 2 3 4 5 
 
Intermittency 
Over the past month, how often have you found you 
stopped and started again several times when you 
urinated? 
0 1 2 3 4 5 
 
Urgency 
Over the last month, how difficult have you found it to 
postpone urination? 
0 1 2 3 4 5 
 
Weak stream 
Over the past month, how often have you had a weak 
urinary stream? 
0 1 2 3 4 5 
 
Straining 
Over the past month, how often have you had to push or 
strain to begin urination? 
0 1 2 3 4 5 
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Nocturia 
Over the past month, many times did you most typically get 
up to urinate from the time you went to bed until the time 
you got up in the morning? 
0 1 2 3 4 5 
 
 
Total IPSS score 
 
 
 
Quality of life due to urinary symptoms 
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If you were to spend the rest of your life with your urinary 
condition the way it is now, how would you feel about that? 0 1 2 3 4 5 6 
 
Total score: 0-7 Mildly symptomatic; 8-19 moderately symptomatic; 20-35 severely symptomatic. 
 

MASTER CHART – MONOPOLAR 
S.NO NAME AGE MO/BI 
PREOPERATIVE POSTOPERATIVE      PRE OP  PERI OP     POST OP OTHERS 
Q 
MAX IPPS Hb PCV   Na QOL 
Q 
MAX IPPS Hb PCV Na QoL VOL CATH DM HT DM+HT 
OP 
TIME CLOT 
TUR 
S 
F T 
VOID 
1 MANIKKAM 60 MONO 9.5 19 11.5 34 137 4 18.5 10 10.6 31 134 2 46 N Y N N 54 N N N 
2 AMARESAN 62 MONO 10.8 25 11.9 34 139 3 17.5 15 11.1 33 135 2 26 N N Y N 35 N N N 
3 PONNUSAMY 65 MONO 10 21 12 36 141 4 18.4 14 11.3 34 136 2 35 N N N N 41 N N N 
4 BALAN 73 MONO NA 23 12.5 37 138 5 NA 13 11.9 35 132 2 29 Y Y N N 35 N N N 
5 ABDUL MAHAROOF 70 MONO 9.5 24 11.6 33 142 4 17.5 14 11 33 135 2 36 N N N N 41 N N N 
6 GOVINDASAMY 73 MONO NA 26 12.5 34 141 5 NA 15 11.9 35 135 2 27 Y N N N 35 N N N 
7 SIVAPRAKASAM 80 MONO 10.5 24 10.2 30 137 4 17.6 14 9.5 28 131 1 32 N N N N 39 N N N 
8 MURUGESAN 65 MONO 8.4 21 11.6 33 140 4 17.1 11 11 33 135 2 36 N Y Y Y 40 N N N 
9 SHANMUGAM  70 MONO 11.1 23 11.5 34 136 3 18.8 12 11.2 33 132 1 28 N N N N 37 N N N 
10 MOHAMAD ALI 59 MONO 11.5 25 11.8 34 139 4 18.5 14 11 33 135 2 29 N N N N 38 N N N 
11  GAJINIKHAN 51 MONO 10.6 24 12.3 36 135 3 17.5 12 11.5 34 131 2 32 N N N N 40 N N N 
12 KRISHNAN 78 MONO NA 22 11.9 35 140 6 NA 12 11 33 132 3 34 Y N N N 42 N N N 
13 SUBRAMANI 65 MONO 10.2 19 11.5 34 142 5 17.6 10 10.4 31 137 2 29 N N N N 36 N N N 
14 KASIPILLAI 70 MONO 9.5 24 12.6 37 146 4 18.4 12 11.5 34 140 2 31 N N N N 40 N N N 
15 THULUKKANAM 65 MONO 10.5 25 13.5 39 145 3 19.4 13 12.8 38 139 2 32 N Y Y Y 42 N N N 
16 MUTHUSAMY 73 MONO 10.8 26 12.5 36 138 3 17 13 11.9 35 132 2 39 N N N N 45 N N N 
17 KRISHNAPPAN 62 MONO 9.5 24 11.3 33 137 4 17.1 12 10.7 32 130 2 42 N N N N 48 N N N 
18 ANNAMALAI 65 MONO 11.2 26 11 33 135 4 16.6 15 10.4 31 129 2 29 N N N N 37 N N N 
19 ETHIYAPPAN 54 MONO 9.4 25 12.9 38 141 3 16.8 14 12.3 36 134 1 48 N N N N 53 N N N 
20 MANIKANDAN 76 MONO NA 23 10.6 33 139 5 NA 12 10 30 133 2 32 Y N N N 39 N N Y 
21 ELUMALAI 72 MONO 11.2 27 11.8 34 144 4 18.5 14 11 33 135 1 34 N N N N 40 N N N 
22 ANTONY 73 MONO 10.2 24 11.6 33 135 3 17.6 13 11.1 33 129 1 27 N Y Y Y 35 N N N 
23 DHAKSHINAMOORTHI 60 MONO 9.2 24 12.9 37 139 5 18.6 13 12.1 36 123 2 50 N N N N 55 N Y N 
24 VENKATESAN 65 MONO 8.1 26 13.5 39 137 4 17.5 14 12.6 37 134 3 28 N N N N 36 N N N 
25 SARAVANAN 60 MONO 8.8 21 14.5 43 135 3 16.7 11 13.8 39 128 1 38 N N N N 42 N N N 
MASTER CHART – MONOPOLAR 
S.NO NAME AGE MO/BI 
PREOPERATIVE POSTOPERATIVE      PRE OP  PERI OP     POST OP OTHERS 
Q 
MAX IPPS Hb PCV   Na QOL 
Q 
MAX IPPS Hb PCV Na QoL VOL CATH DM HT DM+HT 
OP 
TIME CLOT 
TUR 
S 
F T 
VOID 
26 PARTHASARATHI 70 MONO 9.5 23 12.5 36 139 4 17.8 12 11.8 35 131 2 37 N N N N 43 N N N 
27 PANDI 69 MONO 10.5 24 13.5 39 140 3 19.2 12 12.8 37 133 2 38 N Y N N 46 N N N 
28 KULANTHIVELU 75 MONO NA 20 13.5 39 145 5 NA 10 12.9 37 138 3 36 Y N N N 42 N N N 
29 PARTHASARATHI 60 MONO 9.1 23 13 39 142 4 18.5 12 12.5 36 135 2 41 N N Y N 48 N N N 
30 UTHARAPPAN 50 MONO 11 24 14.2 41 143 4 19.4 13 13.5 40 139 2 42 N N N N 46 N N N 
31 MUTHUSAMY 73 MONO 10.5 21 12.8 37 142 4 17.5 13 11.9 35 135 2 37 N N N N 41 N N Y 
32 ETHIRAJ 70 MONO 9.1 19 12.1 36 140 4 17.8 11 11.4 34 134 1 38 N Y Y Y 43 Y N N 
33 CHINNADURAI 65 MONO 7.5 25 11.9 34 135 3 17.1 14 11.2 33 128 1 29 N N N N 37 N N N 
34 MUNUSAMY 57 MONO 10.5 24 12.5 37 138 4 16.9 12 11.7 35 131 2 38 N N N N 46 N N N 
35 SUBRAYAN 65 MONO 9 22 12.4 36 137 5 18 11 11.6 35 131 2 29 N Y N N 37 N N N 
36 SUBRAMANI 65 MONO 9.5 26 12.8 37 140 3 17.5 15 12.2 36 134 2 39 N N N N 45 N N N 
37 SELVARAJ 60 MONO 8.6 25 13.2 39 139 4 16.5 14 12.5 37 132 2 45 N N N N 48 N N N 
38 NATARAJAN 70 MONO NA 23 11.3 33 142 5 NA 13 10.5 31 135 2 30 Y N N N 40 N N N 
39 LAKSHMANAN 75 MONO 9 22 10.9 32 136 4 18.5 12 10.2 30 130 1 36 N N N N 44 N N N 
40 KANNAIYAN 65 MONO 10.2 21 11.8 35 141 4 17.6 13 11.3 30 134 2 27 N Y Y Y 35 N N N 
41 DEVENDRA RAO 67 MONO 7.5 22 12.1 36 138 3 17.5 11 11.5 33 132 1 41 N N N N 48 N N N 
42 VENKATESAN 65 MONO 9.2 23 12.6 37 139 4 17.6 12 11.8 35 133 2 27 N N N N 35 N N N 
43 SARAVANAN 60 MONO 11 25 13.1 39 137 4 17.1 15 12.4 36 132 3 43 N N N N 50 N N N 
44 MUNUSAMY 64 MONO 9.5 24 12.1 36 143 4 17.6 14 11.4 33 136 2 35 N N N N 40 N N N 
45 VELU 51 MONO 10.6 21 13.9 40 139 3 18.5 12 13.2 39 132 1 37 N N N N 41 N N N 
46 NARAYANAN 62 MONO 8.5 26 12.6 37 135 4 16.8 15 12 36 129 2 38 N N N N 45 N N N 
47 PACHAIYAPPAN 56 MONO 9.3 25 13.5 40 145 4 17.5 15 12.4 37 132 2 32 N N N N 40 N N N 
48 GIDDAMAI 59 MONO 10 21 13.9 40 144 3 17.2 12 13.1 39 136 1 38 N N Y N 45 Y N N 
49 THANGAVEL 60 MONO 9.8 19 12.4 36 136 3 17.5 10 11.8 35 130 2 28 N N N N 36 N N N 
50 ABDUL RASHID 59 MONO 9.5 23 13.5 39 140 4 17.6 12 12.9 38 135 1 36 N Y N N 41 N N N 
MASTER CHART – MONOPOLAR 
S.NO NAME AGE MO/BI 
PREOPERATIVE POSTOPERATIVE      PRE OP  PERI OP     POST OP OTHERS 
Q 
MAX IPPS Hb PCV   Na QOL 
Q 
MAX IPPS Hb PCV Na QoL VOL CATH DM HT DM+HT 
OP 
TIME CLOT 
TUR 
S 
F T 
VOID 
51 RAJAN 65 MONO 7.5 25 12.6 36 138 5 16.5 14 12 36 132 1 39 N N N N 46 N N N 
52 KESAVAN 58 MONO 9.5 25 12.9 38 142 4 17.6 14 12.2 36 135 2 40 N N N N 45 N N N 
53 SELVARAJ 70 MONO NA 23 11.5 33 139 5 NA 11 10.8 32 132 3 27 Y N N N 34 N N N 
54 PERUMAL 80 MONO NA 23 10.5 31 136 4 NA 12 9.8 29 130 3 35 Y N N N 40 N N N 
55 NATARAJAN 65 MONO 9.1 24 11.6 32 145 4 17.6 14 10.9 33 138 2 30 N N Y N 38 Y N N 
56 GOVINDASAMY 60 MONO 10.5 26 12.1 36 144 3 19.5 15 11.5 34 135 2 38 N N N N 42 N N N 
57 ADHIMOOLAM 51 MONO 10 25 13.1 39 143 4 17.6 15 12.6 38 138 2 37 N Y N N 44 N N N 
58 YESURATHINAM 65 MONO 9.5 22 11.2 33 139 4 18.4 10 10.6 32 132 2 30 N N N N 37 N N N 
59 ARUMUGAM 55 MONO 10.5 21 12.5 36 137 3 18.5 11 11.5 34 130 1 37 N N N N 44 N N N 
60 CHAKRAPANI 70 MONO NA 23 11.9 35 142 5 NA 13 11.2 33 125 2 58 Y N Y N 56 N Y N 
61 RAMDOSS 54 MONO 7 21 13.5 40 136 4 16.9 11 12.8 38 130 2 38 N N N N 44 N N N 
62 ARULNATHAN 68 MONO 8.5 23 12.4 36 140 3 17.1 12 11.8 34 133 1 40 N N N N 45 N N N 
63 GNAPRAKASAM 54 MONO 9 22 13.4 39 138 4 16.5 11 12.7 38 131 2 30 N N N N 40 N N N 
64 DURAIRAJ 62 MONO 7.5 21 12.1 36 139 4 17.1 12 11.6 35 132 2 29 N N N N 37 N N N 
65 MUNUSAMY 70 MONO NA 19 12.3 36 143 5 NA 10 11.6 34 135 3 27 Y N N N 35 N N N 
66 RAMASAMY 68 MONO 9.5 22 12.4 37 140 4 18.1 13 11.7 35 133 2 35 N N N N 41 N N N 
67 DURAISAMY 64 MONO 9.1 23 12.5 38 137 3 18.4 13 11.6 35 131 1 38 N Y Y Y 42 N N N 
68 SUBRAMANI 58 MONO 9.5 24 12.3 36 142 4 17.6 12 11.3 34 135 2 39 N N N N 44 N N N 
69 JANAKIRAMAN 63 MONO 9.1 22 12.6 36 136 3 17.4 11 11.8 35 130 1 36 N N N N 42 N N N 
70 AZEEZ 70 MONO NA 23 11.3 33 141 5 NA 13 10.5 31 134 3 35 Y N N N 42 N N Y 
71 JEGANATHAN 57 MONO 9 25 12.9 37 143 4 17.5 15 12.1 36 136 2 41 N N N N 47 N N N 
72 GANESAN 68 MONO 8.5 21 11.5 33 138 5 18.5 12 10.9 32 131 2 38 N Y N N 43 N N N 
73 KASI 60 MONO 10.5 23 13.4 39 136 4 18.5 13 12.7 37 129 2 38 N N N N 42 N N N 
74 SAMPATH 60 MONO 9.2 23 12.9 38 142 4 18.4 15 12.3 37 136 2 34 N N Y N 40 N N N 
75 RAVI 52 MONO 10.5 27 13.5 39 141 3 18.4 17 12.9 35 134 2 48 N N N N 52 N N N 
MASTER CHART – BIPOLAR 
S.NO NAME AGE MO/BI 
PREOPERATIVE POSTOPERATIVE      PRE OP  PERI OP     POST OP OTHERS 
Q 
MAX IPPS Hb PCV   Na QOL 
Q 
MAX IPPS Hb PCV Na QoL VOL CATH DM HT DM+HT 
OP 
TIME CLOT 
TUR 
S 
F T 
VOID 
1 AYYANAR 62 BI 8.3 21 11.5 34 135 4 18.8 14 11.1 33 131 2 28 N Y N N 42 N N N 
2 MOHAMAD ALI 67 BI 9.1 23 10.9 33 141 3 16.5 14 10.4 31 136 2 31 N N N N 48 N N N 
3 NAGAN 73 BI 10.9 20 12.8 38 137 4 18.2 13 12.2 35 132 3 33 N N N N 49 N N N 
4 ANNAMALAI 69 BI 7.2 23 11.5 34 138 4 17.1 14 10.9 32 133 2 36 N Y N N 50 N N N 
5 CHENGALVARAYAN 75 BI 11.1 24 12 36 139 3 18.1 14 11.3 33 135 2 27 N N Y N 47 N N N 
6 GANAPATHIRATHINAM 76 BI 10.9 21 11.7 34 140 4 17.5 13 11.2 33 135 2 41 N N N N 48 N N N 
7 KASI 70 BI NA 22 10.5 32 143 5 NA 14 9.9 29 138 2 41 Y N N N 50 Y N N 
8 ELUMALAI 70 BI 10.1 21 12.7 37 140 4 18.6 15 11.9 35 135 3 36 N Y N N 45 N N N 
9 BALARAMAN 74 BI 8.3 21 10.5 31 134 4 17.1 12 9.9 29 130 2 43 Y N N N 51 Y Y Y 
10 POOMANIKKAM 65 BI 9.1 23 11.2 33 141 3 16.5 14 10.6 31 137 2 27 N N N N 40 N N N 
11 BALAI JOSEPH 61 BI NA 20 11.5 34 139 5 NA 13 10.9 32 135 2 30 Y N N N 43 N N N 
12 CHINNAIH 70 BI 10.9 20 11.5 33 138 4 17.2 10 10.8 32 133 2 36 N N N N 46 N N N 
13 RAMACHANDRAN 56 BI 10.3 23 13.8 40 143 5 17.5 11 13.1 36 139 2 35 N N N N 45 N N N 
14 VENUGOPAL 60 BI 9.1 22 14.1 40 137 3 18.1 13 13.5 39 132 3 37 N N N N 45 N N N 
15 RAMAIH 72 BI 10.5 23 12.9 38 145 4 16.5 12 12.2 36 141 2 32 N Y Y Y 44 N N N 
16 NATESAN 70 BI 10.1 21 12.1 36 144 4 18.8 14 11.5 33 139 2 29 N N N N 40 N N N 
17 KRISHNAN 82 BI NA 24 10.9 33 139 5 NA 15 10.3 30 135 2 36 Y N N N 46 N N N 
18 SELVARAJ 55 BI 9.3 21 11.8 34 142 4 17.2 12 11.1 33 138 2 27 N N N N 36 N N N 
19 MURUGESAN 60 BI 7.5 24 10.6 32 141 4 16.5 13 9.9 29 137 1 38 N N N N 47 N N N 
20 SHANMUGAM  75 BI 11.5 23 10.9 33 135 3 17.5 12 10.3 30 131 2 29 N N N N 39 N N N 
21 RANGARAJ 70 BI 10.1 24 10.2 31 134 3 17.6 13 9.6 28 130 2 36 N N N N 46 N N N 
22 KANNIYAPPAN 70 BI 9.2 25 11.7 34 141 5 16.7 14 11.1 32 137 1 38 N Y Y Y 49 N N Y 
23 PASUPATHI 77 BI NA 24 12.1 36 145 4 NA 12 11.5 33 141 3 49 Y N N N 52 N N N 
24 KUPPUSAMY 83 BI 8 21 10.1 31 138 3 16.9 14 9.5 28 134 2 29 N N N N 39 N N N 
25 VELUSAMY 56 BI 10.5 22 14.5 41 137 4 18.5 13 13.8 39 129 2 52 N N N N 57 N N N 
MASTER CHART – BIPOLAR 
S.NO NAME AGE MO/BI 
PREOPERATIVE POSTOPERATIVE      PRE OP  PERI OP     POST OP OTHERS 
Q 
MAX IPPS Hb PCV   Na     
Q 
MAX IPPS Hb PCV   Na     
Q 
MAX IPPS Hb 
26 PALANI 67 BI 10.5 23 13.4 39 141 4 19 15 12.7 37 137 2 38 N N N N 46 N N N 
27 MANOKARAN 55 BI 9.2 24 14.4 40 142 5 17.6 12 13.8 39 138 1 36 N Y N N 45 N N N 
28 PRAKASAM 65 BI 8.2 20 12.4 37 136 4 17.5 11 12 35 131 2 39 N N N N 46 N N N 
29 PARI 57 BI 10 21 13.6 40 145 3 18 10 13.1 39 141 1 36 N N Y N 45 N N N 
30 VELAYUTHAM 56 BI 11.8 21 13.5 39 137 4 17.6 12 13 38 133 2 38 N N N N 46 N N N 
31 RAI 62 BI 9.3 19 12.4 36 139 3 17.1 10 11.9 35 134 1 37 N N N N 44 N N N 
32 SANTHAIAH 60 BI 7.8 25 12.9 38 135 4 16.2 13 12.4 36 131 2 29 N Y Y Y 40 N N N 
33 ARULAPPAN 70 BI NA 22 12 36 146 6 NA 12 11.5 33 143 3 39 Y N N N 47 N N N 
34 SEBASTIN 52 BI 10 23 12.3 36 142 4 17.5 14 11.8 34 138 1 33 N N N N 41 N N N 
35 MUNUSAMY 55 BI 9.1 25 14 41 137 4 18.1 15 13.5 39 133 2 39 N Y N N 47 N N N 
36 KASI 60 BI 11.8 25 13.5 40 141 3 17.3 14 12.9 38 136 1 41 N N N N 48 N N N 
37 ETHIRAJ 70 BI NA 23 11.8 34 137 6 NA 13 11.2 33 132 2 29 Y N N N 40 N N N 
38 MUNUSAMY 58 BI 10 22 12.8 37 142 4 16.9 13 12.5 37 137 2 28 N N N N 39 N N N 
39 RANGASAMY 65 BI 8.3 21 11.6 33 139 4 17 12 11.1 33 134 2 38 N N N N 46 N N N 
40 GULSAR 50 BI 9 21 13.7 40 135 3 18.2 13 13.4 39 131 1 41 N Y Y Y 48 N N N 
41 VEDI 57 BI 10.8 23 14 41 139 4 18.5 13 13.5 39 134 2 38 N N   N 46 N N N 
42 ETHIRAJ 60 BI 7.5 25 12.9 37 145 3 18.2 14 12.4 36 140 2 49 N N N N 52 N N N 
43 VELSAMY 56 BI 9.3 24 13.5 40 142 4 16.1 15 12.8 37 138 2 33 N N N N 41 N N N 
44 VEDI 51 BI 10 23 13.9 39 141 3 18.5 12 13.3 39 136 1 29 N N N N 40 N N N 
45 PERUMAL 65 BI 9.5 25 12.5 36 137 4 17.6 14 11.9 35 133 2 28 N N N N 39 N N N 
46 SUBBURAYAN 80 BI NA 20 10.1 30 139 5 NA 10 9.5 28 136 1 33 Y N N N 41 Y N N 
47 ELUMALAI 70 BI 10.1 26 12.1 36 140 4 17.4 15 11.5 34 136 2 39 N N N N 45 N N N 
48 CHIINNA 65 BI 8.8 19 12.4 37 135 3 17.3 11 11.8 35 131 2 45 N N Y N 50 N N N 
49 MURUGAN 75 BI NA 24 12.5 36 139 4 NA 12 11.9 35 135 2 37 Y N N N 45 N N N 
50 ANNAMALAI 78 BI 8.2 23 11.5 33 142 3 17.8 13 10.8 32 138 1 25 N Y N N 35 N N N 
MASTER CHART – BIPOLAR 
S.NO NAME AGE MO/BI 
PREOPERATIVE POSTOPERATIVE      PRE OP  PERI OP     POST OP OTHERS 
Q 
MAX IPPS Hb PCV   Na     
Q 
MAX IPPS Hb PCV   Na     
Q 
MAX IPPS Hb 
51 GOVINDASAMY 61 BI 10 25 11.9 35 145 4 18.5 15 11.3 33 141 1 35 N N N N 42 N N N 
52 MARIMUTHU 73 BI 10.5 23 12.5 37 144 4 19.6 14 11.9 34 140 2 41 N N N N 48 N N N 
53 CHINNAPPAN 74 BI 9.5 22 11.6 35 136 3 17.6 12 10.9 32 132 1 29 N N N N 38 N N N 
54 KOTHANDARAJ 65 BI 7.5 26 11.6 35 139 4 16.4 15 11.1 33 136 2 37 N N N N 46 N N N 
55 RAJI 59 BI 9.1 24 13.1 39 140 4 17.4 13 12.5 36 136 2 39 N N Y N 46 N N N 
56 ELLAPPAN 80 BI NA 26 10.5 32 142 5 NA 17 9.9 28 138 2 34 Y N N N 46 N N N 
57 RAJARATHINAM 61 BI 10.1 27 11.1 33 141 4 17.6 16 10.5 31 138 2 31 N Y N N 41 N N N 
58 GOVINDASAMY 56 BI 10.5 25 12.6 36 137 4 18.6 14 12.1 36 133 2 35 N N N N 46 N N N 
59 THIRUMALAI 65 BI 9.5 23 12.5 36 136 4 18.1 12 12 35 132 2 29 N N N N 38 N N N 
60 GOPAL 70 BI NA 24 12.5 37 139 5 NA 12 11.9 35 135 2 41 Y N Y N 47 N N N 
61 SUBRAMANI 65 BI 10.5 23 12.5 36 142 4 18.6 13 11.9 34 138 1 34 N N N N 46 N N N 
62 KANNADASAN 65 BI 9 24 12.6 36 140 3 17.8 14 12.1 36 136 1 29 N N N N 39 N N N 
63 KRISHNAN 65 BI 9.5 25 13.3 39 139 4 17.6 13 12.8 37 135 2 38 N N N N 45 N N N 
64 JEEVARATHINAM 82 BI NA 25 11.2 33 135 5 NA 16 10.7 32 130 2 51 Y N N N 55 N N N 
65 MURUGAN 57 BI 10.5 24 13.5 39 142 4 19.6 13 12.9 38 138 2 41 N N N N 49 N N N 
66 GOVINDAPILLAI 70 BI 10.6 21 11.2 33 141 4 18.1 13 10.6 34 137 2 39 N N N N 47 N N N 
67 CHAKRAPANI 55 BI 9.1 21 12.2 36 138 4 17.9 10 11.7 35 134 2 38 N Y Y Y 45 N N N 
68 MARUTHAMUTHU 78 BI 10.8 23 13.5 39 135 3 18.6 11 12.9 38 131 1 35 N N N N 43 N N N 
69 RANGAN 68 BI 7.2 22 12.5 36 136 5 16.1 10 12.1 36 133 3 35 N N N N 47 N N N 
70 BALAJI 61 BI 8 23 11.6 33 142 3 16.5 13 11.1 33 138 2 36 N N N N 45 N N N 
71 VENKATESAN 70 BI NA 23 12.9 37 144 6 NA 11 12.2 36 140 1 29 Y N N N 38 Y N N 
72 THANGAPANDI 55 BI 9.5 24 13.4 39 140 4 17.5 12 12.9 38 136 1 35 N N N N 46 N N N 
73 THULASINATHAN 77 BI 9.8 23 13.7 39 135 4 17.9 12 13 38 131 2 26 N N N N 39 N N N 
74 SHANMUGAM 74 BI 8.1 21 13.4 38 138 4 16.8 12 12.9 37 135 1 42 N N Y N 47 N N N 
75 SUBBURAJ 65 BI 7 23 12.6 37 139 3 17.4 13 12.1 35 135  37 N N N N 44 N N N 

 
